Abstract
In the last few years, the role of neoadjuvant hormonal treatment (NHT) prior to radical prostatectomy has been largely debated and investigated in randomized multicenter trials as well as in large single-institution studies. We have initiated a prospective randomized comparative trial with parallel groups in patients with clinically limited disease to contribute to the clarification of the possible role of NHT; to evaluate the efficacy of NHT with leuprolide plus cyproterone acetate in 'maintaining' the stage of the disease; to reduce the percentage of pathological overstaging, and mainly to accurately assess the pathological modifications induced by NHT. The present paper is an interim report of the results.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / pathology
-
Adenocarcinoma / surgery
-
Aged
-
Androgen Antagonists / administration & dosage
-
Antineoplastic Agents, Hormonal / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma in Situ / drug therapy
-
Carcinoma in Situ / pathology
-
Carcinoma in Situ / surgery
-
Carcinoma, Squamous Cell / drug therapy
-
Carcinoma, Squamous Cell / pathology
-
Carcinoma, Squamous Cell / secondary
-
Carcinoma, Squamous Cell / surgery
-
Chemotherapy, Adjuvant
-
Cyproterone Acetate / administration & dosage
-
Delayed-Action Preparations
-
Diagnosis, Differential
-
Disease-Free Survival
-
Drug Administration Schedule
-
Humans
-
Leuprolide / administration & dosage*
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Prospective Studies
-
Prostatectomy
-
Prostatic Diseases / pathology
-
Prostatic Hyperplasia / pathology
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / pathology*
-
Prostatic Neoplasms / surgery
Substances
-
Androgen Antagonists
-
Antineoplastic Agents, Hormonal
-
Delayed-Action Preparations
-
Cyproterone Acetate
-
Leuprolide